Elaine Sun appointed to the board of directors at Asher Bio
Asher Biotherapeutics has announced that Elaine Sun has been appointed to the Board of Directors. Asher Bio is a biotechnology company with a focus on developing therapies to engage specific immune cells to fight cancer.
Sun currently works as the chief operating officer and chief financial officer of Mammoth Biosciences, and brings more than 25 years of experience to her new role. She has also previously worked as senior vice president and chief financial officer at Halozyme Therapeutics, and chief financial officer and chief strategy officer at SutroVax (now known as Vaxcyte).
Craig Gibbs PhD, chief executive officer at Asher Bio, commented: “We are excited to welcome Elaine to our Board, as she brings exceptional strategic, operational and financial experience and leadership to our organisation. Elaine’s impressive track record of creating value in the biopharmaceutical industry and fostering the growth of both early- and late-stage biotechnology companies will be a tremendous resource for Asher Bio as we advance our pipeline of precision immunotherapies into the clinic.”
Sun added: “I am impressed with the potential of Asher Bio’s cis-targeting platform to transform immunotherapy and the team’s tremendous progress in advancing its pipeline candidates into the clinic. The company’s ongoing development of potential therapies intended to precisely engage specific immune cells to address disease areas with high unmet need positions Asher Bio to stand out in the field and potentially deliver important new medicines that could lead to meaningfully improved treatment options for patients. I am honoured to join Asher Bio’s board and look forward to working with the management team and other Board members at this pivotal stage for the company.”